{"created":"2021-03-01T06:09:49.770139+00:00","id":5950,"links":{},"metadata":{"_buckets":{"deposit":"9f5ad9ae-88fc-4387-aef3-586c542b499f"},"_deposit":{"id":"5950","owners":[],"pid":{"revision_id":0,"type":"depid","value":"5950"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00005950","sets":["453:455","471:561:562"]},"item_6_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Phase I dose finding study of the addition of docetaxel to gefitinib beyond progressive disease"}]},"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-09-20","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"20","bibliographicPageStart":"1","bibliographic_titles":[{}]}]},"item_6_date_granted_51":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2017-09-20"}]},"item_6_degree_grantor_49":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"新潟大学"}]}]},"item_6_degree_name_48":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"［目的］ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対する、ゲフィチニブ継続下でのドセタキセル併用療法の最大耐用量（MTD）および推奨用量（RD）を決定すること。［方法］ゲフィチニブで治療効果を認めた後に病勢が進行したPS 0-1、20歳以上の非小細胞肺癌症例に対して、ゲフィチニブ（250 mg/day）は連日投与で継続し、ドセタキセル（level 1：50 mg/m^2、同2：60 mg/m^2、同3：70 mg/m^2）をday1に投与し3週間で1コースとした。用量制限毒性（DLT）は4日以上続くgrade 4の好中球減少、grade 4の血小板減少、2週間を超える投与の延期、grade 3以上の非血液毒性とし、1コース目で評価した。［結果］Level 1に4例、level 2に5例、level 3に5例の計14例が登録された。ドセタキセルの投与コース数中央値は4コースであった。DLTはlevel 2に1例（4日間以上のgrade 4の好中球減少）、level 3に1例（4日間以上のgrade 4の好中球減少と発熱性好中球減少症の併発）認められた。評価可能症例における奏効割合は43%、病勢制御率は100%であった。Level 3（ドセタキセル70 mg/m^2）におけるDLTは5例中1例であったが、全例でgrade 4の好中球減少が出現しG-CSFの投与を必要としたことなどから、レベル3をMTDとした。RDと決定されたlevel 2の奏効割合は40%であった。［結論］本治療法の忍容性は良好であり、抗腫瘍効果が示唆された。","subitem_description_type":"Abstract"}]},"item_6_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"学位の種類: 博士（医学）. 報告番号: 甲第4354号. 学位記番号: 新大院博（医）甲第767号. 学位授与年月日: 平成29年9月20日","subitem_description_type":"Other"}]},"item_6_description_53":{"attribute_name":"学位記番号","attribute_value_mlt":[{"subitem_description":"新大院博（医）甲第767号","subitem_description_type":"Other"}]},"item_6_dissertation_number_52":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"13101甲第4354号"}]},"item_6_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"51135","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Ota, Takeshi"}]}]},"item_6_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟大学"}]},"item_6_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"ETD"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"太田, 毅"}],"nameIdentifiers":[{"nameIdentifier":"51134","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-05"}],"displaytype":"detail","filename":"h29nmk767.pdf","filesize":[{"value":"682.3 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"本文","url":"https://niigata-u.repo.nii.ac.jp/record/5950/files/h29nmk767.pdf"},"version_id":"ae1af8e9-9c7b-4178-9c5d-70e0e6e4f3db"},{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-05"}],"displaytype":"detail","filename":"h29nmk767_a.pdf","filesize":[{"value":"188.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"要旨","url":"https://niigata-u.repo.nii.ac.jp/record/5950/files/h29nmk767_a.pdf"},"version_id":"1445a54a-8e3b-4e04-a655-e23e076258c5"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"非小細胞肺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"ゲフィチニブ","subitem_subject_scheme":"Other"},{"subitem_subject":"ドセタキセル","subitem_subject_scheme":"Other"},{"subitem_subject":"第I相臨床試験","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"thesis","resourceuri":"http://purl.org/coar/resource_type/c_46ec"}]},"item_title":"ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験"},{"subitem_title":"ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験","subitem_title_language":"en"}]},"item_type_id":"6","owner":"1","path":["455","562"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-11-07"},"publish_date":"2017-11-07","publish_status":"0","recid":"5950","relation_version_is_last":true,"title":["ゲフィチニブで病勢抑制後進行した非小細胞肺癌に対するゲフィチニブ継続ドセタキセル併用療法の第Ⅰ相試験"],"weko_creator_id":"1","weko_shared_id":2},"updated":"2022-12-15T03:39:13.169243+00:00"}